The company entered into an agreement for the lease of the comprehensive facility, which will allow it to carry out research as well as manufacture microspheres for its lead product candidate AB101, a once-weekly basal insulin for the treatment of diabetes.
AntriaBio chairman and chief executive officer Nevan Elam said, "Establishing our manufacturing and research presence is an exciting and critical step forward for the Company, as we are now poised to work as an integrated team to make clinical material for AB101 and advance that program through the next phase of development."
The 27,000ft² facility includes separate laboratory space, manufacturing suites and office space.
Laboratory and manufacturing equipment acquired by AntriaBio through the acquisition of PR Pharmaceuticals’s intellectual property and assets in 2013, will be moved into the new facility and will be used for AB101, as well as other potential pipeline candidates.